Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy

Authors

Pavel Klein, MedStar Research Institute, Washington, DCFollow
Daniel Herr, MedStar Research Institute, Washington, DC
Phillip L. Pearl, George Washington UniversityFollow
JoAnne Natale, Children's National Medical Center, Washington, DC
Zachary Levine, MedStar Research Institute, Washington, DC
Claude Nogay, MedStar Research Institute, Washington, DC
Fabian Sandoval, MedStar Research Institute, Washington, DC
Stacey Trzcinsky, Children's National Medical Center, Washington, DC
Shireen M. Atabaki, Children's National Medical Center, Washington, DCFollow
Tammy Tsuchida, George Washington UniversityFollow
John van den Anker, George Washington UniversityFollow
Steven J. Soldin, Children's National Medical Center, Washington, DC
Jianping He, Children's National Medical Center, Washington, DC
Robert McCarter, Children's National Medical Center, Washington, DC

Document Type

Journal Article

Publication Date

8-2012

Journal

Epilepsy and Behavior

Volume

Volume 24, Issue 4

Inclusive Pages

457-461

Keywords

Anticonvulsants--pharmacokinetics; Anticonvulsants--therapeutic use; Epilepsy--prevention & control; Piracetam--analogs & derivatives

APA Citation

Klein, P., Herr, D., Pearl, P.L., Natale, J., Levine, Z., Nogay, C., Sandoval, F., Trzcinsky, S., Atabaki, S.M., Tsuchida, T., van den Anker, J., Soldin, S.J., He, J., McCarter, R. (2012). Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. Epilepsy and Behavior, 24(4), 457-461.

Peer Reviewed

1